Read twice and referred to the Committee on Finance.
This bill amends Medicare law to extend prescription drug inflation rebate rules to drugs sold in the commercial market for both Medicare Part B and Part D.
It changes multiple base/reference dates (moving them back to 2015–2016 dates) which will alter rebate calculations, adds exclusions (for Medicaid-paid units, previously rebated units, and, beginning 2026, 340B discounted units), and requires use of manufacturer AMP and state reports for calculations.
Part D amendments take effect for applicable periods beginning October 1, 2025; Part B changes apply to quarters beginning January 1, 2026.
Technically targeted and potentially popular but faces well‑organized industry resistance and requires interchamber compromise on technical changes.
Relative to its intended legislative type, this bill is a clearly focused substantive statutory amendment that specifies the legal mechanics to extend prescription drug inflation rebates to commercial-market drugs and updates base-year references. It integrates with existing statutory reporting structures and sets effective dates for implementation.
Liberal emphasizes consumer savings and closing loopholes
Liberal emphasizes consumer savings and closing loopholes
Likely supportive: this extends inflation-based rebates into the commercial market and uses an earlier base year, increasing manufacturer rebate obligations and discouraging price hikes.
Seen as closing loopholes and strengthening data use to lower out-of-pocket costs for patients.
Cautious, pragmatic support if the bill demonstrably reduces costs and implementation burdens are contained.
Wants fiscal scoring, phased rollout, and clear administrative rules to avoid disruption to providers and beneficiaries.
Likely opposed: views this as expanded federal intrusion into commercial drug markets and an unfriendly pricing rule worsening regulatory burden.
Concerned the earlier base year and broader scope will impose costs and deter innovation.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technically targeted and potentially popular but faces well‑organized industry resistance and requires interchamber compromise on technical changes.
The bill has not accumulated any surfaced votes yet.
Liberal emphasizes consumer savings and closing loopholes
Technically targeted and potentially popular but faces well‑organized industry resistance and requires interchamber compromise on technical…
Relative to its intended legislative type, this bill is a clearly focused substantive statutory amendment that specifies the legal mechanics to extend prescription drug inflation rebates to commercial-market drugs and u…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.